Dale Weil - Theratechnologies Independent Director

TH Stock  CAD 1.74  0.06  3.57%   

Director

Ms. Dale Weil is Director of the company. She brings close to 35 years of business development experience, much of which was acquired while working with McKesson Canada, a diversified healthcare company and the largest pharmaceutical distributor in the country. At McKesson Canada, Ms. Weil has held various leadership positions, most recently as senior advisor to the president since 2017.
Age 63
Tenure 7 years
Address 2015 Peel Street, Montreal, QC, Canada, H3A 1T8
Phone514 336 7800
Webhttps://www.theratech.com
Weil holds a Bachelor degree in Marine Biology and a Master degree in Business Administration, both from McGill University.

Theratechnologies Management Efficiency

The company has return on total asset (ROA) of 0.1176 % which means that it generated a profit of $0.1176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.1686) %, meaning that it generated substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 1.39, while Return On Tangible Assets are likely to drop (0.44). At this time, Theratechnologies' Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Other Assets is likely to grow to about 2.2 M, while Total Assets are likely to drop about 65.2 M.
Theratechnologies has accumulated 58.97 M in total debt with debt to equity ratio (D/E) of 6.46, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Theratechnologies has a current ratio of 1.86, which is within standard range for the sector. Debt can assist Theratechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Theratechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theratechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theratechnologies to invest in growth at high rates of return. When we think about Theratechnologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

DIRECTOR Age

Edgar PangAdvent Wireless
N/A
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada. THERATECHNOLOGIES operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 42 people. Theratechnologies (TH) is traded on Toronto Exchange in Canada and employs 103 people. Theratechnologies is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Theratechnologies Leadership Team

Elected by the shareholders, the Theratechnologies' board of directors comprises two types of representatives: Theratechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theratechnologies. The board's role is to monitor Theratechnologies' management team and ensure that shareholders' interests are well served. Theratechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theratechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
MarieNoel Colussi, Vice President - Finance
Jovan Antunovic, Senior Vice President and Chief Commercial Office
Conor Walshe, General Manager - Theratechnologies Europe Limited
Sheila Frame, Independent Director
Paul Lvesque, CEO President
Philippe Dubuc, Chief Financial Officer, Senior Vice President
Paul Levesque, President, Chief Executive Officer, Director
Andrew Molson, Independent Director
Gerald Lacoste, Independent Director
LLB LLM, General Secretary
Dawn Svoronos, Independent Chairman of the Board
Pierre Perazzelli, Vice President - Pharmaceutical Development
LLB BA, VP Affairs
Denis Boucher, Vice President - Communications and Corporate Affairs
H MSc, Vice Resources
Christian Marsolais, Senior Vice President - Scientific Affairs and Alliances
John Leasure, Global Officer
Paul Pommier, Independent Director
Gilles Cloutier, Independent Director
Gary Littlejohn, Independent Director
Elif McDonald, Director Relations
Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary
Alain Trudeau, Independent Director
MBA MBA, Senior CFO
Dale Weil, Independent Director

Theratechnologies Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theratechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Theratechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Theratechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theratechnologies will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Theratechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Theratechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Theratechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Theratechnologies to buy it.
The correlation of Theratechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Theratechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Theratechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Theratechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Theratechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theratechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theratechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theratechnologies Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Please note, there is a significant difference between Theratechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Theratechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theratechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.